You are here

Eliquis

J&J snaps up key label expansion for Xarelto

J&J snaps up key label expansion for Xarelto

Biopharma Dive

Flag link:

BMS, Pfizer's fast-growing Eliquis is about to steamroll market-leader warfarin: executive

BMS, Pfizer's fast-growing Eliquis is about to steamroll market-leader warfarin: executive

Fierce Pharma

Bristol-Myers Squibb

Flag link:

How Bristol-Myers and Pfizer are using real-world data to unseat warfarin

How Bristol-Myers and Pfizer are using real-world data to unseat warfarin

Biopharma Dive

Bristol-Myers Squibb

real world evidence

Flag link:

Bristol-Myers calls on real-world evidence to unseat warfarin

Bristol-Myers calls on real-world evidence to unseat warfarin

Biopharma Dive

Bristol-Myers Squibb

Flag link:

5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them

5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them

Motley Fool

Bristol-Myers Squibb

Flag link:

After 5 years, Eliquis' growth ceiling is nowhere in sight: Bristol-Myers CEO

After 5 years, Eliquis' growth ceiling is nowhere in sight: Bristol-Myers CEO

Fierce Pharma

Bristol-Myers Squibb

Giovanni Caforio

Flag link:

Bristol-Myers, Pfizer continue to build case for Eliquis

Bristol-Myers, Pfizer continue to build case for Eliquis

BioPharma Dive

Bristol-Myers Squibb

Flag link:

Bristol-Myers, Pfizer come up victorious in 20 more Eliquis bleeding cases

Bristol-Myers, Pfizer come up victorious in 20 more Eliquis bleeding cases

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Bristol-Myers Squibb recalls mislabeled Eliquis medications

Bristol-Myers Squibb recalls mislabeled Eliquis medications

BioPharma Dive

Bristol-Myers Squibb

Flag link:

BMS and Pfizer file 16 Eliquis patent lawsuits to waylay generic makers

BMS and Pfizer file 16 Eliquis patent lawsuits to waylay generic makers

Fierce Pharma

Bristol-Myers Squibb

patent lawsuits

Flag link:

Bristol-Myers and Pfizer's Eliquis outperforms rivals versus warfarin

Bristol-Myers and Pfizer's Eliquis outperforms rivals versus warfarin

BioPharma Dive

Bristol-Myers Squibb

Flag link:

Many at risk for stroke don’t get anti-clotting drugs

Many at risk for stroke don’t get anti-clotting drugs

Reuters

atrial fibrillation

Flag link:

Pfizer's 3 Fastest-Growing Drugs

Pfizer's 3 Fastest-Growing Drugs

Motley Fool

Flag link:

Bristol-Myers Squibb Saw Improved Eliquis Sales in 3Q16

Bristol-Myers Squibb Saw Improved Eliquis Sales in 3Q16

Market Realist

Bristol-Myers Squibb

Flag link:

Eliquis Proving to Be a Major Growth Driver for Pfizer This Year

Eliquis Proving to Be a Major Growth Driver for Pfizer This Year

Market Realist

Flag link:

Why Eliquis Matters to Bristol-Myers Squibb’s Cardiovascular Business

Why Eliquis Matters to Bristol-Myers Squibb’s Cardiovascular Business

Yahoo/Market Realist

Bristol-Myers Squibb

Flag link:

BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa

BMS expects fast-growing Eliquis to take the lead over Xarelto, Pradaxa

Fierce Pharma Marketing

Bristol-Myers Squibb

Boehringer Ingelheim

Flag link:

4 Blockbuster Drugs Whose Sales Could Easily Double

4 Blockbuster Drugs Whose Sales Could Easily Double

Motley Fool

Bristol-Myers Squibb

Flag link:

How can Pradaxa, Xarelto and Eliquis finally unseat warfarin? Safety data, analyst says

How can Pradaxa, Xarelto and Eliquis finally unseat warfarin? Safety data, analyst says

Fierce Pharma

Boehringer Ingelheim

Bristol-Myers Squibb

Flag link:

J&J-Bayer and Pfizer-BMS look for marketing advantages in real-world Xarelto, Eliquis data

J&J-Bayer and Pfizer-BMS look for marketing advantages in real-world Xarelto, Eliquis data

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Pages